Compare Novo Nordisk A/S (NVO) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Total World Stock Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $44.75 (market cap $200.69B), while Vanguard Total World Stock Index Fund ETF trades at $160.99. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VT | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $162.39 |
52-Week Low | $35.29 | $134.19 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
VT trades at $160.92, down 0.5% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF offers broad global equity diversification with over 10,000 stocks and a low 0.06% expense ratio. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced holdings.
The outlook remains favorable for long-term investors seeking global exposure, supported by cost efficiency and diversification benefits. Risks include trade policy uncertainty and market volatility, but VT's structure mitigates single-country or sector risks. Analyst sentiment is generally positive, emphasizing its role as a core holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
